



Webcast Alert: Aastrom to Host Investor Conference Call and Webcast on June 11, 2010 Following Presentation at Society for Vascular Surgery Meeting

ANN ARBOR, Mich., June 4, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) announces the following webcast:

What: Conference call and webcast of the presentation of interim results from Aastrom's U.S. Phase 2b RESTORE-CLI clinical trial which will be presented at the Vascular Annual Meeting[®] of the Society for Vascular Surgery. The event will also feature a Q&A session with Richard J. Powell, M.D., section chief of vascular surgery at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire.

When: Friday, June 11, 2010 @ 3:30 pm (ET)

Where: <http://www.investorcalendar.com/IC/CEPage.asp?ID=159248>

How:

- Live **Internet** access is available at: <http://www.investorcalendar.com/IC/CEPage.asp?ID=159248>.
- For **phone** access, call toll-free (877) 407-9210 before the start of the call to register for the "Aastrom Conference Call". Any registered caller on the toll-free line may ask the call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8049.
- To download the presentation as a **podcast**, simply log on to the web at the address above.

If you are unable to participate during the live call, the webcast will be available for replay at <http://www.investorcalendar.com/> until September 13, 2010. Through June 18, 2010, the audio replay of the call will be available by calling toll-free (877) 660-6853, or from outside the U.S. by calling (201) 612-7415. Callers must provide account number 286 and Conference ID number 351605 to access the call.

About Aastrom Biosciences

Aastrom Biosciences is developing autologous cellular therapies for use in the treatment of severe cardiovascular diseases. The company's proprietary cell-processing technology enables the production of cellular therapies using a patient's own bone marrow that can be delivered directly to damaged tissues. Aastrom has advanced this technology into late-stage clinical development and is conducting two Phase 2 clinical trials to treat dilated cardiomyopathy and a Phase 2b clinical trial to treat critical limb ischemia. For more information, please visit Aastrom's website at www.aastrom.com.

The Aastrom Biosciences, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=3663>

CONTACT: Berry & Company
Media contact
Stephen Zoegall
212 253-8881
szoegall@berrypr.com

Aastrom Biosciences
Investor Contact
Kimberli O'Meara
734 930-5777
ir@aastrom.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.